ARCT Overview

Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.

Wall Street analysts forecast ARCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARCT is14.00 USD with a low forecast of 7.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Arcturus Therapeutics Holdings Inc revenue for the last quarter amounts to 7.20M USD, decreased -68.39

Arcturus Therapeutics Holdings Inc. EPS for the last quarter amounts to -1.03 USD, decreased -7.21

Arcturus Therapeutics Holdings Inc (ARCT) has 106 emplpoyees as of March 25 2026.

Today ARCT has the market capitalization of 189.01M USD.